Trial intelligence / Profile preview

MARIO phase 3 study of IV echinocandin followed by oral ibrexafungerp versus IV echinocandin followed by oral fluconazole in candidemia and/or invasive candidiasis

CTR20223058Phase 3Suspended

Sponsor

SCYNEXIS, Inc.

Start

Mar 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules

Countries

1